Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
You may also be interested in...
The diagnostics company said the test is scheduled for US launch in Q4 2020.
Qiagen's shareholders said Thermo Fisher's final offer price for the diagnostics company was too low.
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.